Previous studies have indicated that 2,2′-dipyridyl, a lipid-soluble ferrous iron chelator, can reduce brain injury after cerebral ischemia and reduce cerebral vasospasm after subarachnoid hemorrhage. In this study, we examined the efficacy of 2,2′-dipyridyl after intracerebral hemorrhage (ICH) in 12-month-old mice. ICH was modeled by intrastriatal injection of collagenase or autologous whole blood. 2,2′-Dipyridyl or vehicle was administered intraperitoneally 2 h before ICH (pretreatment) or 6 h after ICH (post-treatment) and then once daily for up to 3 days. Mice in the pretreatment group were sacrificed 1 or 3 days after ICH and examined for iron deposition, neuronal death, oxidative stress, microglial/astrocyte activation, neutrophil infiltration, and white matter damage. Mice in the post-treatment group were examined for brain lesion volume and edema on day 3 and for neurologic deficits on days 1, 3, and 28 after ICH. Pretreatment with 2,2′-dipyridyl decreased iron accumulation and neuronal death, attenuated production of reactive oxygen species, reduced microglial activation without affecting astrocytes or neutrophil infiltration, and attenuated white matter damage. Post-treatment reduced brain lesion volume and edema and improved neurologic function. These results indicate that the lipid-soluble ferrous iron chelator 2,2′-dipyridyl can reduce brain injury and improve functional outcome after ICH.
Introduction
Intracerebral hemorrhage (ICH) is a common and often fatal stroke subtype. In the aftermath of ICH, iron, a heme degradation product, contributes significantly to the consequent brain injury (Wang, 2010) . After erythrocyte lysis, iron concentrations in the brain can become high enough to stimulate free radical formation, which, in turn, leads to neuronal death and secondary brain injury (Wagner et al., 2003; Wang, 2010; Xi et al., 2006) . When tested in preclinical studies, the iron chelator deferoxamine has inconsistently shown protection against hemorrhagic brain injury in rats (Okauchi et al., 2009; Warkentin et al., 2010) . Deferoxamine was administered post-ICH in both studies, but in one it was delivered intramuscularly (Okauchi et al., 2009) and in the other intraperitoneally (i.p.) (Warkentin et al., 2010) . In our previous study, we confirmed that iron toxicity contributes to collagenase-induced hemorrhagic brain injury in mice and that reducing iron accumulation by post-treatment with deferoxamine i.p. can improve neuronal survival; however, deferoxamine did not reduce brain lesion volume, edema, or swelling after ICH (Wu et al., 2011) .
Lipid-soluble ferrous iron chelator 2,2′-dipyridyl (DP) has been reported to alleviate brain damage in different rodent models of cerebral ischemia (Demougeot et al., 2004; Methy et al., 2008; Millerot-Serrurot et al., 2008; Van Hoecke et al., 2005) and to reduce cerebral vasospasm in primate and rabbit models of subarachnoid hemorrhage (Horky et al., 1998; Yu et al., 2010) . The lipid solubility of DP is evidenced by its ability to freely enter brain cells and chelate intracellular free iron, thereby reducing iron-induced cell death (Breuer et al., 1995; Kress et al., 2002; Methy et al., 2008) . However, the efficacy of DP has not been tested in ICH models, and its effect on iron deposition, iron-mediated oxidative damage, neuroinflammation, and gray and white matter injury after ICH has not been examined. The objective of this study was, therefore, to investigate the efficacy of DP treatment on ICH outcomes and its effect on iron deposition, iron-mediated oxidative damage, neuroinflammation, and gray and white matter injury. Because the aged population is at greater risk for ICH than are young Neurobiology of Disease 45 (2012) 388-394 
